##  [New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease](/us-en/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-tmca-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease-0 "New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease") 

  Nov 15, 2019